Skip to main content

Martin Henry Poleski

Professor of Medicine
Medicine, Gastroenterology
Duke Box 3662, Durham, NC 27710
0351D Duke South Bldg, Orange Zone, Durham, NC 27710

Selected Publications


Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Journal Article Arch Pathol Lab Med · September 2018 CONTEXT: - Graft-versus-host disease of the gastrointestinal tract is a common complication of hematopoietic stem cell transplant associated with significant morbidity and mortality. Accurate diagnosis can be difficult and is a truly clinicopathologic ende ... Full text Link to item Cite

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.

Journal Article Biol Blood Marrow Transplant · April 2018 Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smal ... Full text Link to item Cite

The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.

Journal Article Dig Dis Sci · March 2016 BACKGROUND: Graft-versus-host disease (GVHD) complicates half of hematopoietic stem cell transplants (HCT), and the gastrointestinal tract is commonly affected. Endoscopic biopsies have a key role in the diagnosis. The optimal procedure(s) to perform and s ... Full text Link to item Cite

Management of adverse events associated with idelalisib treatment: expert panel opinion.

Journal Article Leuk Lymphoma · 2015 Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical t ... Full text Link to item Cite

Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial.

Journal Article JOP · September 10, 2012 CONTEXT: Animal studies have demonstrated a role for substance P binding to neurokinin-1 receptor in the pathogenesis of acute pancreatitis. OBJECTIVE: Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post ... Full text Link to item Cite

Management of dieulafoy's lesions

Journal Article · December 1, 2010 In 1884 Gallard wrote the first description of a patient with a Dieulafoy's lesion [1]. The lesion's name, however, comes from Paul Georges Dieulafoy (1839-1911), a professor of pathology at the Faculty of Medicine in Paris. In 1898 Dieulafoy described sev ... Full text Cite

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.

Journal Article Oncologist · 2010 INTRODUCTION: Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer ... Full text Link to item Cite

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

Journal Article Oncologist · 2010 We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized ... Full text Link to item Cite

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Journal Article Cancer Res · October 15, 2009 Clinical studies converge on the observation that circulating cytokines are elevated in most cancer patients by anti-vascular endothelial growth factor (VEGF) therapy. However, the source of these molecules and their relevance in tumor escape remain unknow ... Full text Link to item Cite

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

Journal Article J Clin Oncol · June 20, 2009 PURPOSE: To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response. PATIENTS AND METHODS: In a phase I/II study, 32 patients received four cycles of th ... Full text Link to item Cite

Inflammatory bowel disease following solid organ transplantation.

Journal Article Clin Immunol · September 2008 Inflammatory bowel disease (IBD) is a T cell driven inflammatory condition of the gut. Following solid organ transplantation (SOT), de novo IBD has been reported despite anti-T cell therapy for the prevention of organ rejection. This paradox is illustrated ... Full text Link to item Cite

Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia.

Journal Article J Clin Gastroenterol · August 2008 GOALS: We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia. BACKGROUND: Gastroesophageal variceal ... Full text Link to item Cite

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.

Journal Article Nat Clin Pract Oncol · May 2007 BACKGROUND: Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I-II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here i ... Full text Link to item Cite

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

Journal Article Gastroenterology · April 1997 BACKGROUND & AIMS: The efficacy of mesalamine for the maintenance of remission in patients with Crohn's disease is controversial. The aim of this study was to conduct a double-blind, placebo-controlled study of mesalamine (750 mg four times a day for 48 we ... Full text Link to item Cite

Effects of pirenzepine on acute mucosal erosions, gastric acid and mucosal blood flow in the spinal rat stomach.

Journal Article Digestion · 1991 Featured Publication The aim of this study was to examine the effects of varying doses of pirenzepine, a selective muscarinic subtype M1 antagonist, on the prevention of acute gastric mucosal lesions in male Sprague-Dawley rats subjected to spinal cord section at the C7 level. ... Full text Link to item Cite

Screening for carcinoma of the colon: Pitfalls of the Hemoccult® test

Journal Article Problems in General Surgery · January 1, 1987 Colorectal carcinoma fulfills most of the criteria for disease screening. It occurs frequently in the general population, early detection results in longer survival, and premalignant polyps can often be detected and eradicated. Occult blood testing is safe ... Cite

Sensitivity of the Hemoccult II slide test in detecting colonic neoplasms.

Journal Article Can J Surg · March 1986 Featured Publication It is common clinical practice to test stools for occult blood and to rely heavily upon the result in deciding whether to investigate further. Because the accuracy of such testing has been questioned, a study was conducted to estimate the sensitivity of th ... Link to item Cite

Cimetidine versus antacids in the prevention of stress erosions in critically ill patients.

Journal Article Am J Gastroenterol · February 1986 Featured Publication To assess the efficacy of cimetidine versus Mylanta II in the prevention of stress erosions, 44 patients at risk were randomized to receive cimetidine 300 mg/6 h intravenously to a maximum of 400 mg/4 h; or Mylanta II 30 ml/h through a nasogastric tube to ... Link to item Cite

Acid neutralization capacity of Canadian antacid formulations.

Journal Article Can Med Assoc J · August 1, 1985 Featured Publication Link to item Cite

Abdominal pain and weight loss in a patient with well controlled diabetes.

Journal Article Can Med Assoc J · July 1, 1985 Featured Publication Link to item Cite

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Journal Article Arch Pathol Lab Med · September 2018 CONTEXT: - Graft-versus-host disease of the gastrointestinal tract is a common complication of hematopoietic stem cell transplant associated with significant morbidity and mortality. Accurate diagnosis can be difficult and is a truly clinicopathologic ende ... Full text Link to item Cite

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.

Journal Article Biol Blood Marrow Transplant · April 2018 Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smal ... Full text Link to item Cite

The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.

Journal Article Dig Dis Sci · March 2016 BACKGROUND: Graft-versus-host disease (GVHD) complicates half of hematopoietic stem cell transplants (HCT), and the gastrointestinal tract is commonly affected. Endoscopic biopsies have a key role in the diagnosis. The optimal procedure(s) to perform and s ... Full text Link to item Cite

Management of adverse events associated with idelalisib treatment: expert panel opinion.

Journal Article Leuk Lymphoma · 2015 Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical t ... Full text Link to item Cite

Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial.

Journal Article JOP · September 10, 2012 CONTEXT: Animal studies have demonstrated a role for substance P binding to neurokinin-1 receptor in the pathogenesis of acute pancreatitis. OBJECTIVE: Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post ... Full text Link to item Cite

Management of dieulafoy's lesions

Journal Article · December 1, 2010 In 1884 Gallard wrote the first description of a patient with a Dieulafoy's lesion [1]. The lesion's name, however, comes from Paul Georges Dieulafoy (1839-1911), a professor of pathology at the Faculty of Medicine in Paris. In 1898 Dieulafoy described sev ... Full text Cite

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.

Journal Article Oncologist · 2010 INTRODUCTION: Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer ... Full text Link to item Cite

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

Journal Article Oncologist · 2010 We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized ... Full text Link to item Cite

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Journal Article Cancer Res · October 15, 2009 Clinical studies converge on the observation that circulating cytokines are elevated in most cancer patients by anti-vascular endothelial growth factor (VEGF) therapy. However, the source of these molecules and their relevance in tumor escape remain unknow ... Full text Link to item Cite

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

Journal Article J Clin Oncol · June 20, 2009 PURPOSE: To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response. PATIENTS AND METHODS: In a phase I/II study, 32 patients received four cycles of th ... Full text Link to item Cite

Inflammatory bowel disease following solid organ transplantation.

Journal Article Clin Immunol · September 2008 Inflammatory bowel disease (IBD) is a T cell driven inflammatory condition of the gut. Following solid organ transplantation (SOT), de novo IBD has been reported despite anti-T cell therapy for the prevention of organ rejection. This paradox is illustrated ... Full text Link to item Cite

Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia.

Journal Article J Clin Gastroenterol · August 2008 GOALS: We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia. BACKGROUND: Gastroesophageal variceal ... Full text Link to item Cite

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.

Journal Article Nat Clin Pract Oncol · May 2007 BACKGROUND: Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I-II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here i ... Full text Link to item Cite

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

Journal Article Gastroenterology · April 1997 BACKGROUND & AIMS: The efficacy of mesalamine for the maintenance of remission in patients with Crohn's disease is controversial. The aim of this study was to conduct a double-blind, placebo-controlled study of mesalamine (750 mg four times a day for 48 we ... Full text Link to item Cite

Effects of pirenzepine on acute mucosal erosions, gastric acid and mucosal blood flow in the spinal rat stomach.

Journal Article Digestion · 1991 Featured Publication The aim of this study was to examine the effects of varying doses of pirenzepine, a selective muscarinic subtype M1 antagonist, on the prevention of acute gastric mucosal lesions in male Sprague-Dawley rats subjected to spinal cord section at the C7 level. ... Full text Link to item Cite

Screening for carcinoma of the colon: Pitfalls of the Hemoccult® test

Journal Article Problems in General Surgery · January 1, 1987 Colorectal carcinoma fulfills most of the criteria for disease screening. It occurs frequently in the general population, early detection results in longer survival, and premalignant polyps can often be detected and eradicated. Occult blood testing is safe ... Cite

Sensitivity of the Hemoccult II slide test in detecting colonic neoplasms.

Journal Article Can J Surg · March 1986 Featured Publication It is common clinical practice to test stools for occult blood and to rely heavily upon the result in deciding whether to investigate further. Because the accuracy of such testing has been questioned, a study was conducted to estimate the sensitivity of th ... Link to item Cite

Cimetidine versus antacids in the prevention of stress erosions in critically ill patients.

Journal Article Am J Gastroenterol · February 1986 Featured Publication To assess the efficacy of cimetidine versus Mylanta II in the prevention of stress erosions, 44 patients at risk were randomized to receive cimetidine 300 mg/6 h intravenously to a maximum of 400 mg/4 h; or Mylanta II 30 ml/h through a nasogastric tube to ... Link to item Cite

Acid neutralization capacity of Canadian antacid formulations.

Journal Article Can Med Assoc J · August 1, 1985 Featured Publication Link to item Cite

Abdominal pain and weight loss in a patient with well controlled diabetes.

Journal Article Can Med Assoc J · July 1, 1985 Featured Publication Link to item Cite

Cimetidine and gastric carcinoma.

Journal Article Ann Intern Med · May 1983 Full text Link to item Cite

Kaposi's sarcoma and hepatitis B vaccine.

Journal Article Ann Intern Med · November 1982 Full text Link to item Cite

Prevention of stress ulcers in rats by cimetidine and pentagastrin

Journal Article Gastroenterology · January 1, 1980 Cite

Abdominal mass in an elderly woman.

Journal Article N Engl J Med · September 21, 1978 Link to item Cite

The value of diagnostic aids in detecting pancreas cancer.

Journal Article Cancer · March 1978 By contract with the National Cancer Institute, the accuracy of diagnostic techniques was assessed in 184 patients suspected of having pancreas cancer. Of 138 patients who were operated upon, 89 were found to have pancreas duct cancer, 30 had cancer of a d ... Full text Link to item Cite